358 related articles for article (PubMed ID: 18687517)
1. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
[TBL] [Abstract][Full Text] [Related]
2. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
[TBL] [Abstract][Full Text] [Related]
3. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD
Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124
[TBL] [Abstract][Full Text] [Related]
4. ELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO.
Lausen J; Liu S; Fliegauf M; Lübbert M; Werner MH
Oncogene; 2006 Mar; 25(9):1349-57. PubMed ID: 16247445
[TBL] [Abstract][Full Text] [Related]
5. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
6. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.
Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ
J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927
[TBL] [Abstract][Full Text] [Related]
7. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
8. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
9. A distinct epigenetic signature at targets of a leukemia protein.
Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
[TBL] [Abstract][Full Text] [Related]
10. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
11. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
Kohzaki H; Ito K; Huang G; Wee HJ; Murakami Y; Ito Y
Oncogene; 1999 Jul; 18(28):4055-62. PubMed ID: 10435586
[TBL] [Abstract][Full Text] [Related]
12. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
13. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
14. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
15. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1.
Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD
Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431
[TBL] [Abstract][Full Text] [Related]
16. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
Tokita K; Maki K; Mitani K
Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
[TBL] [Abstract][Full Text] [Related]
17. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
18. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.
Choi Y; Elagib KE; Delehanty LL; Goldfarb AN
Cancer Res; 2006 Mar; 66(6):2990-6. PubMed ID: 16540647
[TBL] [Abstract][Full Text] [Related]
19. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines.
Gu L; Chiang KY; Zhu N; Findley HW; Zhou M
Exp Hematol; 2007 Jun; 35(6):957-66. PubMed ID: 17533050
[TBL] [Abstract][Full Text] [Related]
20. PIG7, transactivated by AML1, promotes apoptosis and differentiation of leukemia cells with AML1-ETO fusion gene.
Liu J; Xing H; Chen Y; Wang L; Wang D; Rao Q; Tang K; Tian Z; He K; Wang M; Wang J
Leukemia; 2012 Jan; 26(1):117-26. PubMed ID: 21836606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
